| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director
4 companies
Albert Cha is Director at ACRS and has filed Form 4s across 4 companies. Albert Cha's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $32.6M at current prices.
The biggest single holding is ACRS (~$15.7M) as Director. Net of sales, the ACRS filings show accumulation of 467,897 shares.
Albert Cha has 19 Form 4 filings on record from April 2015 to October 2026, across 4 companies: Chief Executive Officer at Frazier Life Sciences Acquisition Corp. II Class A Ordinary Shares (FLSC), 2026; Director at KalVista Pharmaceuticals (KALV), 2015–2023; Director at VYNE Therapeutics (VYNE), 2018, and 1 more.
The 41 reported transactions were 18 open-market purchases, 11 conversions, 9 option or other derivative awards and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 9 purchases worth about $40.3M and 1 sale worth about $189K.
The largest open-market purchase was 1,058,824 shares of KALV at an average $17.00 on September 10, 2018, about $18.0M.
The only open-market sale was 18,000 shares of KALV at an average $10.50 on September 11, 2023, about $189K. Twelve months later KALV was up 6%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | FLSC Frazier Life Sciences Acquisition Corp. II Class A Ordinary Shares | Chief Executive Officer | Buy | 300,000 | $10.00 | $3,000,000.00 | New | - | - | |
| Sep 11, 2023 | KALV Kalvista Pharmaceuticals, Inc. | Director | Sale+OE | 18,000 | $10.50 | $189,050.40 | - | -16.6% | +6.4% | |
| Oct 30, 2020 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 115,686 | $17.24 | $1,994,067.74 | +11.3% | - | - | |
| Jul 29, 2019 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 56,367 | $16.99 | $957,737.10 | +82.7% | - | - | |
| Jul 19, 2019 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 61,280 | $17.79 | $1,090,295.69 | +6.7% | - | - | |
| Sep 10, 2018 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 1,058,824 | $17.00 | $18,000,008.00 | +352.6% | - | - | |
| Jan 25, 2018 | VYNE Vyne Therapeutics Inc. | Director | Buy | 294,118 | $17.00 | $5,000,006.00 | -113.8% | - | - | |
| Oct 13, 2015 | ACRS Aclaris Therapeutics, Inc. | Director | Buy | 454,545 | $11.00 | $4,999,995.00 | +12.2% | - | - | |
| Oct 7, 2015 | ACRS Aclaris Therapeutics, Inc. | Director | Buy | 13,352 | $11.00 | $146,872.00 | +4.6% | - | - | |
| Apr 14, 2015 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 1,012,500 | $5.00 | $5,062,500.00 | +31.7% | - | - |